Kiesewetter D O, Kawai R, Chelliah M, Owens E, McLellan C, Blasberg R G
Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
Int J Rad Appl Instrum B. 1990;17(4):347-56. doi: 10.1016/0883-2897(90)90100-f.
Three 18F-labeled benzamide derivatives were prepared and evaluated as potential ligands to study the dopamine D2 receptor phenomenon. The compounds are analogs of iodobenzamide, eticlopride and raclopride and are labeled with an N-2-[18F]fluoroethyl functionality on the pyrrolidine ring. The compounds were tested in vitro for binding affinity and found to exhibit somewhat lower affinity than the non-fluorinated analog. In vivo distribution studies revealed that all compounds were more highly bound to plasma proteins than was raclopride. In addition, compartmentation of radioactivity demonstrated nonspecific binding to be the predominate retention in the brain as reflected by the low caudate to cerebellum ratios for these compounds. These three 18F-labeled benzamide derivatives are inferior to raclopride and iodobenzamide for studies of the D2 receptor system using positron emission tomography.
制备了三种18F标记的苯甲酰胺衍生物,并将其作为潜在配体进行评估,以研究多巴胺D2受体现象。这些化合物是碘苯酰胺、依替必利和雷氯必利的类似物,在吡咯烷环上标记有N-2-[18F]氟乙基官能团。对这些化合物进行了体外结合亲和力测试,发现其亲和力比非氟化类似物略低。体内分布研究表明,所有化合物与血浆蛋白的结合都比雷氯必利更强。此外,放射性的区室化表明,非特异性结合是大脑中主要的滞留方式,这从这些化合物尾状核与小脑的低比率中可以看出。对于使用正电子发射断层扫描研究D2受体系统而言,这三种18F标记的苯甲酰胺衍生物不如雷氯必利和碘苯酰胺。